Salivary duct carcinoma (SDC) is an aggressive subtype of primary salivary gland
carcinoma, often with an advanced stage at presentation and high rates of metastasis and�…

Salivary duct carcinoma (SDC) is a rare, aggressive salivary malignancy that is often
diagnosed at an advanced stage. Previously, little was known about outcomes of this�…

Accurate diagnosis of salivary gland tumors can be challenging because of the many
diagnostic entities, the sometimes extensive morphologic overlap, and the rarity of most�…

Salivary duct carcinoma (SDC) is an aggressive salivary gland malignancy with poor
survival. Approximately 30% SDC harbor HER2 amplification and response to trastuzumab�…

With the advent of targeted therapies, expression of sex hormone receptors and HER-2 in
salivary gland tumors (SGTs) is of clinical interest. Previous reports of estrogen (ER) and�…

Salivary gland carcinomas are rare tumours and therapy strategies are less standardized
than in lung, gastric or breast cancer. Therapy is based on surgery, but not all carcinomas�…

Background Salivary ductal carcinoma and carcinoma ex pleomorphic adenoma (CEPA) are
aggressive salivary gland cancers with poor prognosis. The standard of care is resection�…

The aim of the present study was to investigate the expression of the transcription factor Ki-
67, ER, PR, Her2/neu, p21, EGFR, and TOP II-${\alpha} $ in the tumor tissue of patients with�…

Combination of docetaxel, trastuzumab and pertuzumab or treatment with trastuzumab-emtansine
for metastatic salivary duct carcin Page 1 Letter to the editor Combination of docetaxel�…

Background The role of molecular markers in salivary gland carcinoma (SGC) is not well
understood. We evaluated molecular marker expression and their prognostic value�…